Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/197660
Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter's Transformation
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
CART19 cells are emerging as an alternative therapy for patients with chronic lymphocytic
leukemia (CLL). Here we report the outcome of nine consecutive patients with CLL treated
with ARI-0001 CART19 cells, six of them with Richter’s transformation (RT). One patient
with RT never received therapy. The cytokine release syndrome rate was 87.5% (12.5%
grade ≥3). Neurotoxicity was not observed in any patient. All patients experienced
absolute B-cell aplasia, and seven (87.5%) responded to therapy. With a median
follow-up of 5.6 months, two patients with RT experienced a CD19-negative relapse. In
conclusion, ARI-0001 cell therapy was feasible, safe, and effective in patients with high risk CLL or RT
Matèries (anglès)
Citació
Citació
ORTIZ-MALDONADO GIBSON, Valentín, et al. Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter's Transformation. Frontiers In Oncology. 2022. Vol. 12, num. 828471. ISSN 2234-943X. [consulted: 6 of August of 2026]. Available at: https://hdl.handle.net/2445/197660